Пептидные аналоги эпитопов взаимодействия протеина А с иммуноглобулинами класса G, их синтез и исследование целевых свойств

Using methods of theoretical conformational analysis, the Phe-Gln-Phe-Tyr-OMe tetrapeptide has been designed and synthesized. Amino acid fragments of this tetrapeptide are present in the active center of protein A, providing its binding with the Fc-fragment of human IgG antibodies. Activity of this tetrapeptide has been confirmed by studies of its binding affinity with Fc-fragment of human IgG antibodies.С помощью методов теоретического конформационного анализа отобрана структура и осуществлен синтез тетра-пептида формулы Phe-Gln-Phe-Tyr-OMe, аминокислотные остатки которого входят в состав активного центра протеина А, обеспечивающего его связывание с Fc-фрагментом иммуноглобулинов класса G. Активность данного тетрапеп-тида подтверждена исследованиями аффинности связывания с Fc-фрагментом иммуноглобулинов класса G

Разработка гемосорбентов для связывания IgG на основе олигопептидных лигандов

The possibility for development of new hemosorbents based on oligopeptide analogues of Staphylococcus aureus protein A epitopes and polyethylene matrix, is discussed. A convenient method for hemosorbent preparation has been developed and primary tests have been performed.Рассматривается возможность создания новых гемосорбентов на основе олигопептидных аналогов эпитопов протеина А Staphylococcus aureus и полиэтиленовой матрицы. Предложена удобная методика получения гемосор-бентов и проведены первичные экспериментальные испытания

Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates

Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: Awareness warranted for 2017/18 season

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65–79-year-olds and 13% (95% CI: −15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate